SCHEMBL29299575

SCHEMBL29299575

CC(C)CCCNC(=O)CCOCCOCCNC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 4/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
CNR1 P21554 2/20 0.36
CNR2 P34972 1/20 0.36
GLP1R P43220 3/20 0.34
ADRB2 P07550 2/20 0.34
ADRB1 P08588 2/20 0.34
HRH3 Q9Y5N1 1/20 0.33
CASP2 P42575 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25792664 0.98 HPGD (0.42) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL26700970 0.96 HPGD (0.40) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL23319057 0.96 HPGD (0.40) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL29299850 0.96 HPGD (0.40) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL23320101 0.94 GLP1R (0.40) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL29299838 0.94 HPGD (0.41) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL26034458 0.90 TSHR (0.41) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL20466149 0.90 MEN1 (0.44) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL20466152 0.90 MEN1 (0.44) HPGDTSHRMEN1KMT2AKDM4E
SCHEMBL25855560 0.89 TSHR (0.41) HPGDTSHRMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R HPGD 2098/4885TSHR 76/4885MEN1 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.